PSC
DFTX

Patient Square Capital’s Definium Therapeutics DFTX Stock Holding History

Patient Square Capital’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.26M Buy
+331,000
New +$5.62M 1.11% 23

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Patient Square Capital's DFTX Position: Q1 2026 in Review

Patient Square Capital opened a new position in Definium Therapeutics (DFTX) in Q1 2026: 331,000 shares worth $6.26M. The stake represents 1.11% of the portfolio and ranks #23 among its holdings.

247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Patient Square Capital held 331,000 shares of Definium Therapeutics worth $6.26M as of Q1 2026.
  • Definium Therapeutics was a new Patient Square Capital position in Q1 2026.
  • Definium Therapeutics made up 1.11% of Patient Square Capital's portfolio in Q1 2026, its #23 holding.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Patient Square Capital's 13F filing for Q1 2026, filed 15 May 2026.